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Abstract
Background: The aim of this study was to determine the clinicopathological features of gastric
cancers with loss of imprinting (LOI) of LIT1. Insulin-like growth factor 2 (IGF2) and H19 in Chinese
patients.
Methods: DNA and RNA from tumours were amplified and then digested with RsaI, ApaI and
HinfI, and RsaI respectively to determine the LOI status. The demographic and clinicopathological
characteristics in LOI positive and LOI negative patients were compared and tested with Statistical
analysis.
Results: Of the 89 patients enrolled for analysis, 22, 40 and 35 were heterozygous and thus
informative for LIT1, IGF2 and H19 LOI analyses respectively. The positive rate of LIT1, IGF2 and
H19 LOI of gastric cancer tissues were 54.6% (12/22), 45% (18/40) and 8.6% (3/32) in Chinese
patients. Gastric corpus cancer (8/10, 80%) were more likely to have LOI of IGF2 in tumours than
antrum cancers (10/30, 33.3%){odds ratio (OR) = 8, 95% confidence intervals (CI) = 1.425-44.920,
p = 0.018)}. LOI of IGF2 in tumours was also associated with the lymph node metastasis (LNM)
(OR = 4.5, 95% CI = 1.084-18.689, p = 0.038).
Conclusion: IGF2 LOI is present in high frequency in Chinese gastric cancer patients, especially
those with gastric corpus cancer.
Background
Genomic imprinting is an epigenetic modification that
leads to the preferential or exclusive expression of a gene
from one of the two parental alleles in somatic cells [1].
Abnormal imprinting involved in a number of human
diseases, particularly, LOI is one of the most frequent
genetic alterations in cancers [2]. LOI can result in either
activation or silencing of the normally silent or expressed
allele of a growth promoting gene or a growth inhibitory
gene, respectively. Research suggests that disruption of
imprinting mechanisms may play a critical role in the
development of cancer [3]. The cluster of imprinted genes
on human chromosome 11p15.5 comprises two
imprinted domains: the IGF2-H19 domain and the
KCNQ1 domain [4]. H19 and IGF2 genes are imprinted
genes and expressed differently depending on whether
they are carried by a chromosome of maternal or paternal
origin [5]; normally IGF2 expression is coordinately regu-
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lated with the maternally expressed H19 gene that pro-
duces a noncoding RNA. But in bladder cancer, paternal
hypomethylation leads to biallelic H19 expression [6],
whereas in Wilms'tumor, maternal hypermethylation and
biallelic IGF2 expression are common [7,8]. The level of
H19 RNAs in Wilms'tumor is also found to inversely cor-
relate with levels of IGF2 mRNA [9], H19 RNAs were
found in polysomes, indicative of H19 translation and/or
potential transregulation of IGF2 translation. The
upstream promoter region of H19 has the imprinting-
control region (ICR) or CTCF binding sites, where the
methylation status of this region is critical to the regula-
tion of imprinting of the H19/IGF2 locus located in chro-
mosome 11p15 [10]. LOI of IGF2 is coupled to abnormal
H19 methylation in the Wilms tumor case [11]. There
may also be an independent mechanism for regulating
IGF2 in Beckwith-Wiedemann syndrome (BWS) patients
[12]. IGF2 encodes a potent mitogenic growth factor that
is active in early development and plays an important role
in embryonic and fetal growth [13]. Increased expression
of IGF2 is a common feature of both pediatric and adult
malignancies since IGF2 binds to the IGF1 receptor to ini-
tiate intracellular signaling cascades that lead to cell pro-
liferation [14]. IGF2 stimulates cell proliferation and
development in normal human growth. Study showed the
overexpressed IGF2 gene is a growth factor for tumors
mediated through both the paracrine and autocrine path-
ways in human cancers. The IGF2 gene may thus play an
important role in lymph vessel permeation especially in
expanding-type gastric cancers [15]. LOI of IGF2 gene is
an important cause of biallelic expression of IGF2 and has
been reported in many different types of tumors including
osteosarcoma [16], lung adenocarcinomas [17], head and
neck squamous cell adenocarcinomas [18], Wilms'tumor
[7], prostate cancer [19], and colorectal carcinomas [20].
Studying mice with Apc-Min/+ model of human familial
adenomatouspolyposis showed excessive expression of
IGF2 resulted increase in the number and the diameter of
colon adenoma and increased susceptibility to colon car-
cinoma [21]. Moreover LOI of IGF2 might provide a
marker for identifying an important subset of the popula-
tion with cancer or at risk of developing cancer [22]. Nor-
mally the KvDMR1 in intron 10 of KCNQ1 unmethylated
paternally promote LIT1/KCNQ1OT1 expressed pater-
nally antisense RNA [23]. The human LIT1 transcription
unit lies within the 11p15.5 imprinted gene cluster and
functions as non-coding RNA [24]. Aberrations of LIT1
expression, such as those caused by LOI, involving aber-
rant hypomethylation and activation of the normally
silent maternal allele and LOI IGF2 have been observed in
Beckwith-Wiedemann syndrome (BWS) and colorectal
cancer [23,25]. In addition, loss of maternal-specific
methylation at the LIT1 locus in BWS and several cancers
correlates with abnormal imprinting status of CDKN1C
[26]. Soejima et al. have recently shown that loss of CpG
and histone H3 methylation at a differentially methylated
region (DMR)-LIT1 leads to a reduction of CDKN1C
expression in esophageal cancer [27]. LOI of IGF2 in gas-
tric tumour tissue except from Taiwan in Chinese and in
Japanese patients [15,28] and the clinicopathological fea-
tures of gastric cancers with LOI of has been reported
rarely. In this study LIT1, IGF2 and H19 imprinting status
in gastric cancer (GC) which is the second most common
cause of cancer-related death in the world was investi-
gated and whether LOI of LIT1, IGF2 and H19 are associ-
ated with clinicopathological features was evaluated. The
study showed LOI of IGF2 is associated with gastric corpus
and LNM in gastric cancer tissues, suggesting that IGF2
plays an important role in gastric carcinogenesis.
Methods
Tissues and information collection
The panel of gastric tissues consisted of paired fresh nor-
mal adjacent-tumorous and tumorous specimens from 89
GC patients during surgery before any other treatment in
the Department of oncology, China Medical University
affiliated the first Hospital from March 2007 to February
2008. Written informed consents were obtained from all
patients. Demographic and clinicopathologic informa-
tion were collected from each patient. Tumour location
was classified as gastric antrum, gastric corpus, gastric car-
dia cancer. The tissues were frozen immediately in an -
80°C freezer until use.
Nucleic acid preparation
After homogenizing the frozen tissues, genomic DNA was
extracted using standard procedures with phenol/chloro-
form and precipitated with ethanol. RNA was extracted
from grounded tissues using guanidinium isothiocyanate-
phenol solution (RNAzol B, Biotecx Laboratories. Inc.,
Houston, TX, USA) following the manufacturer's instruc-
tions. RNA was treated with Rnase-free DNaseI to elimi-
nate DNA contamination (BRL, Baltimore, MD, USA) and
stored at -80°C until use.
Analysis of informative LIT1, IGF2 and H19 cases
Firstly, analyses were performed from DNA of normal tis-
sues to determine informative cases. Heterozygosity in the
LIT1, IGF2 and H19 gene was determined by the presence
or absence of RsaI, ApaI and HinfI, and RsaI sites respec-
tively. Informative genomic heterozygotes for the LIT1,
IGF2 and H19 were studied as follows. The polymorphic
region of LIT1, IGF2 and H19 were amplified with the
primers [25,18] The PCR reaction was conducted in 1 ×
PCR buffer with 1 μm primers, 200 μm dNTP, 2.5 units
Taq DNA polymerase (Perkin-Elmer, Foster City, CA,
USA) and 200 ng genomic DNA. Conditions for amplifi-
cation were 94°C for 2 min followed by 30 cycles at 94°C
for 30 sec, 54 c, 56°C and 58°C (for the LIT1, IGF2 and
H19 respectively) for 1 min, and 72°C for 1 min. A finalJournal of Experimental & Clinical Cancer Research 2009, 28:125 http://www.jeccr.com/content/28/1/125
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step was 72°C for 5 min. The PCR products were subject
to RsaI, ApaI and HinfI and RsaI (New England Biolabs,
Beverly, Mass, USA) enzyme digestion at 37°C overnight,
run through 12% acrylamide gel and stained with ethid-
ium bromide respectively. The expected size of the PCR
fragment of the LIT1 gene is 410 bp. Informative hetero-
zygous cases exhibit three bands of 188, 222 and 410 bp.
For IGF2 Primers P1 and P3 were also used to get a 1.4 kb
DNA fragment that was used as a size control for the RT-
PCR product. PCR conditions were the same except for a
1.5-min annealing step at 60°C C with primers P1 and P3.
The PCR products for IGF2 resulted in a 292 bp band with
primers P2 and P3. Informative cases are those in which
one allele had an ApaI restriction site (256 bp) and the
other had an HinfI restriction site (231 bp). The resultant
655 bp PCR product of H19 yielded additional 487 bp
and 168 bp bands in heterozygotes.
Analysis of LOI of LIT1, IGF2 and H19
RT-PCR at LIT1, IGF2 and H19 were further analysed for
possible allele-specific expression. One microgram total
RNA from heterozygous normal and tumor samples was
reverse transcribed for the first strand cDNA using the
AMV-RT-PCR system (Sangon, Shanghai, China) in a 20
μl reaction. This reaction mixture was added to 80 μl of
100 μM dNTP and 2 mM MgCl2, 10% glycerol and 2.5
units Taq polymerase in 1 × PCR buffer. Amplification
conditions were carried out as described above. For nega-
tive PCR controls, the same primers and reaction condi-
tions with RNA, minus the reverse transcription step were
performed. After RsaI digestion of RT-PCR products,
informative cases of LIT1 with LOI show biallelic expres-
sion of both the 222 and 410 bp, while without LOI,
showing 222 or 410 band. For IGF2, the RT-PCR product
was analysed on 1.5% agarose gel to verify the 1.12 kb
bands, which were smaller than those observed in DNA
analysis (1.4 kb) with the inclusion of 280 bp intron.
Nested PCR wascontinued with the primer P2 as P3 from
this 1.12-kb RT-PCR product, resulting in a 292-bp band.
After digesting the 292-bp cDNA product from the above
RT-PCR reaction with ApaI and HinfI, the presence of
256-bp and 231-bp fragments in a tumor sample indi-
cated biallelic expression. The presence of either the 256
bp or 231 bp band was considered as retention of imprint-
ing. RT-PCR products of H19 resulted in an obvious 575
bp band from cDNA compared to the control of 655 bp
fragment from genomic DNA which includes 80 bp
intron. Constitutive imprinting yielded either a single
575-bp band or 407- and 168-bp bands, LOI resulting in
575-bp, 407- and 168-bp fragments after RsaI digestion.
The threshold for scoring LOI was defined as a ratio of less
than 3-fold difference in expression between two alleles
[29].
Statistical analysis
The prevalence of LOI in patients with gastric cancer was
described as a proportion. The demographic and clinico-
pathological characteristics in LOI positive and LOI nega-
tive patients were compared and tested using the Chi-
Square test. Logistic regression analyses were used to com-
pute the odds ratios (ORs) and 95% confidence interval
(CI). Independent sample t-test was used to compare the
mean age differences between LOI-positive and -negative
patients. All statistical analyses were performed with sta-
tistical software with SPSS version 13.0 for windows
(SPSS, Inc., Chicago IL). All p-values were two-tailed with
0.05 as statistical significance.
Results
Loss of imprinting at LIT1, IGF2 and H19 in gastric cancer 
tissues
We examined the status of genomic imprinting of the
LIT1, IGF2 and H19 genes in 89 gastric cancers by PCR-
restriction fragment length polymorphism (RFLP) analy-
sis (Fig. 1, Fig. 2, Fig. 3). Of the 89 tumours analysed, 22,
40 and 35 cases were heterozygous and thus informative
for LIT1, IGF2 and H19 LOI analyses respectively as
shown in Table 1. LIT1 LOI was observed in 12 of the 22
(54.6%) informative cases, and its LOI was observed in
tumor tissues except only one (4.6%) LIT1 LOI observed
in the adjacent normal tissues. IGF2 LOI was observed in
18 of the 40 (45%) informative cases, and all the cases
showed LOI in the adjacent normal tissues. In five cases
LOI were observed in the normal tissues, but not in the
cancer ones. Only one informative case showed LOI for
both LOI LIT1 and IGF2. We observed only 3 LOI H19 of
the 32 (8.6%) informative tumors cases, and two cases
showed LOI in cancer tissues. In one case, LOI was
observed in the normal tissue, but not in the cancerous tis-
sue.
Table 1: Summary of allele-specific expression in 89 gastric cancers
Gene Informative(n) Imprint LOI Incidence of LOI in tumor
LIT 22 10 12 12/22 (54.6%)
IGF2 40 22 18 18/40 (45%)
H19 35 32 3 3/32 (8.6%)Journal of Experimental & Clinical Cancer Research 2009, 28:125 http://www.jeccr.com/content/28/1/125
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Demographic analysis
The demographic characteristics of patients with or with-
out LOI of LIT1, IGF2 and H19 were shown in Table 2.
There were no differences in the mean age, sex ratio, dia-
betes mellitus(DM), cigarette smoking, alcohol consump-
tion, and family history of GC between the LIT1, IGF2 and
H19 LOI(+) versus (-) respectively.
Clinicopathological features according to LOI LIT1, IGF2 
and H19 status and factors associated with positive LOI 
IGF2
Of the 40 informative IGF2 tumour samples, 30 tumours
were located at the antrum and 10 tumours were located
at the gastric corpus. Gastric corpus cancer (8/10, 80%)
were more likely to have LOI of IGF2 in tumours than
antrum cancers (10/30, 33.3%) (p = 0.028) and the posi-
tive rate of LOI IGF2 was significantly higher in patients
with lymph node metastasis than in those without
(69.2% versus 33.3%, p = 0.033) as shown in Table 3.
There were no differences in the histological differentia-
tion,, hepatic and peritoneal metastasis, lymphatic or
venous invasion, tumour size, stage, Borrmann type and
TNM between the LIT1, IGF2 and H19 LOI(+) versus (-)
respectively. And there were no differences in the tumor
location and lymph node metastasis between the LIT1
and H19 LOI (+) versus(-) respectively. The LOI positive
rate of the LIT1, IGF2 and H19 was higher in patients with
advanced tumour stage than with early stage, but the dif-
ference was not statistically significant (p = 1.000).
Imprinting analysis of LIT1 in gastric cancer Figure 1
Imprinting analysis of LIT1 in gastric cancer. RsaI 
digestion of a 410 bp DNA PCR product (G1, G2) yielded 
bands of 222 and 188 bp indicating heterozygous specimens. 
RsaI digestion of RT-PCR amplification (Rn1, Rn2) showed 
only one allele expression in both normal tissues indicating 
maintenance of constitutional imprinting. Rt1, Rt2 displayed 
three bands in tumor specimens indicating loss of imprinting 
in contrast to their matching normal tissues (Rn1, Rn2). M, 
marker DL2000. Nc1, Nc2 represented RT-PCR without 
reverse transcriptase.
Imprinting analysis of IGF2 in gastric cancer Figure 2
Imprinting analysis of IGF2 in gastric cancer. DNA 
(G1) and RT-PCR (G3) amplification using primers P1 and P3 
and DNA amplification by PCR with primers P2 and P3 (G2) 
represented 1.4 kb, 1.12 kb and 292 bp respectively (see 
details in methods section). G1, G2 and G3 are PCR prod-
ucts of the same normal tissue. ApaI- and HinfI-digested nor-
mal tissue DNA PCR (Gn) from primers P2 and P3 displayed 
two bands of 256 and 231 bp indicating heterozygosity. The 
digested nested PCR product from primers P2 and P3 using 
the 1.12 kb RT-PCR product as a template showed monoal-
lelic expression of IGF2 in normal (Rn1, Rn2) and biallelic 
expression in tumor (Rt1, Rt2) tissues.
Imprinting analysis of H19 in gastric cancer Figure 3
Imprinting analysis of H19 in gastric cancer. H19 het-
erozygosity showed 655 bp DNA PCR product yielded bands 
of 487 and 168 bp by RsaI digestion (G1, G2). Normal tissues 
(N1, N2) showed only one allele expression indicating main-
tenance of normal imprinting (displayed 407 and 168 bp, 575 
bp respectively by RsaI digestion RT-PCR products). T1, T2 
displayed both three bands (575, 407 and 168 bp respec-
tively) in tumor tissues indicating loss of imprinting in con-
trast to their matching normal tissues (N1, N2). M, marker 
DL2000. Nc1, Nc2 represented RT-PCR without reverse 
transcriptase.Journal of Experimental & Clinical Cancer Research 2009, 28:125 http://www.jeccr.com/content/28/1/125
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Tumours with LOI of IGF2 are associated with increased
risk (OR = 8, 95%CI = 1.425-44.920, p = 0.018) of the gas-
tric corpus cancer versus those without LOI and the
increased risk of the lymph node metastasis (OR = 4.5,
95%CI = 1.084-18.689, p = 0.038) as shown in Table 4.
Discussion
The cluster of imprinted genes on human chromosome
11p15.5 consists of two domains: IGF2-H19 domain and
the KCNQ1 domain [4]. LOI of IGF2 has been observed
in 10% of the lymphocytes from normal individuals [30].
In normal human brain, biallelic expression of IGF2 and/
or H19 is found despite differential methylation and
CTCF binding [31]. In this study, we have shown that LOI
of the LIT1, IGF2 and H19 are present in 54.6%, 45% and
8.6% of gastric cancer tissues in Chinese patients respec-
tively. This is the first study to detect on the LOI of LIT1,
IGF2 and H19 in gastric cancer in China-Mainland
patients and LOI of IGF2 positive correlation with gastric
corpus tumour (OR = 8, 95%CI = 1.425-44.920, p =
0.018) and lymph node metastasis (OR = 4.5, 95%CI =
1.084-18.689, p = 0.038).
The frequency of IGF2 LOI (+) gastric cancers (45%, 18/
40) is slightly higher than that reported from Taiwan
(34.5%, 10/29) [28]. High frequency of IGF2 LOI was
observed in tumor and adjacent normal tissues and Igf2
LOI with Apc+/Min mice showed a shift toward less differ-
entiation and an increase in tumor initiation indicating
that IGF2 LOI occur at an early stage in cancer develop-
ment [32]. Although the mechanisms underlying IGF2
LOI in human cancer remains unknown, it is likely to
directly or indirectly involve the H19 ICR. We used the
allele-specific restriction enzyme digestion technique to
identify LOI status, similar to that reported previously
[22]. Some papers have explained the mechanisms in the
tumourigenesis of gastric carcinogenesis [33]. A variety of
epigenetic alterations in human cancers include global
DNA hypomethylation, gene hypomethylation and pro-
moter hypermethylation, and IGF2 LOI. The mechanisms
for LOI are hypermethylation or hypomethylation of a
DMR upstream of the H19 gene, allowing activation of
the normally silent maternal allele of IGF2. LOI may pre-
cede the development of cancer and may thus serve as a
common marker for risk, but also as a model for under-
standing the developmental mechanism for normal
imprinting. Therefore, it is possible that IGF2 LOI play a
role in the tumourigenesis through epigenetic modifica-
tion of DMR. Positive correlations were identified
between elevated IGF2 expression and hypermethylation
of CTCF binding sites at the H19 proximal imprint center
in ovarian cancer [34]. H19 may be a tumor suppressor
gene involved in head and neck carcinogenesis [35]. Epi-
genetic alterations of H19 or LIT1, which encode untrans-
lated RNAs on 11p15, are strongly associated with cancer
risk or specific birth defects in BWS [36].
We found that gastric corpus cancer is associated with
higher IGF2 positive LOI rate, while Liou et al [37] found
that proximal colon cancer is independently associated
with higher positive LOI rate, consistent with a recent
report from Japan [38]. However, larger population are
needed to screen whether IGF2 LOI is involved in which
pathways of gastric carcinogenesis. LOI of LIT1 involves
aberrant hypomethylation and activation of the normally
silent maternal allele. Our data suggest that LIT1 LOI may
Table 2: Demographic data of patients with and without LIT1, AIGF2 and H19 LOI
LIT1
LOI (+)
N = 12
LIT1
LOI (--)
N = 10
P-value IGF2
LOI (+)
N = 18
IGF2
LOI (--)
N = 22
P-value H19
LOI(+)
N = 3
H19
LOI (--)
N = 32
P-value
Gender 1.000 .749 .708
Male 9 (75%) 8 (80%) 14 (77.8%) 15 (68.2%) 3 (100%) 23 (71.9%)
Female 3 (25%) 2 (20%) 4 (22.2%) 7 (31.8%) 0 9 (28.1%)
Mean age, yr (SD) 64.5 (12.4) 61.3 (13.9) 0.574 58.6 (12.4) 62.7 (14.0) .344 68.3 (13.4) 59.7 (13.8) .306
Family history of GC 4 (33.3%) 0 0.096 0 4 (18.2%) .168 0 4 (12.5%) 1.000
DM 0 1 (10%) 0.455 2 (11.1%) 0 .196 0 2 (6.25%) 1.000
Cigarette smoking 10 (83.3%) 7 (70%) 0.816 13 (72.2%) 13 (59.1%) .386 2 (66.7%) 22 (68.8%) 1.000
Alcohol consumption(>10 g/day) 4 (33.3%) 3 (30%) 1.000 6 (33.3%) 5 (22.7%) .695 2 (66.7%) 9 (28.1%) .227
LOI: loss of imprinting; SD: standard deviation; GC: gastric cancer; DM: diabetes mellitusJournal of Experimental & Clinical Cancer Research 2009, 28:125 http://www.jeccr.com/content/28/1/125
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Table 3: Association of clinicopathological features with LIT1, AIGF2 and H19 LOI
LIT1
LOI (+)
N = 12
LIT1
LOI (--)
N = 10
P-value IGF2
LOI (+)
N = 18
IGF2
LOI (--)
N = 22
P-value H19
LOI(+)
N = 3
H19
LOI (--)
N = 32
P-value
Tumor location 1.000 .028 .633
antrum, 10 (83.3%) 8 (80%) 10 (55.6%) 20 (90.9%) 3 (100%) 22 (68.8%)
gastric corpus, 2 (16.7%) 2 (10%) 8 (44.4%) 2 (9.1%) 0 10 (31.2%)
gastric cardia 0 0 0 0 0 0
Histological differentiation 
(well, mod/poor, muc)
5/7 4/6 1.000 9/9 10/12 .775 1/2 15/17 1.000
Lymph node metastasis 5 (41.7%) 4 (40%) 1.000 9 (50%) 4 (18.2%) .033 1 (33.3%) 12 (37.5%) 1.000
Hepatic and peritoneal metastasis 1 (8.3%) 0 1.000 1 (5.6%) 1 (4.6%) 1.000 0 2 (6.25%) 1.000
Lymphatic invasion 4 (33.3%) 1 (10%) .323 4 (22.2%) 4 (18.2%) 1.000 0 8 (25%) .789
Venous invasion 1 (8.3%) 0 1.000 1 (5.6%) 1 (4.6%) 1.000 0 2 (6.25%) 1.000
Tumour Size .746 .332 .423
<2 cm 0 0 3 (16.7%) 6 (27.3%) 0 6 (18.8%)
2--5 cm 8 (66.7%) 6 (60%) 7 (38.9%) 11 (50%) 1 (33.3%) 16 (50%)
>5 cm 4 (33.3%) 4 (40%) 8 (44.4%) 5 (22.7%) 2 (66.7%) 10 (31.3%)
TNM .369 .525 .208
T+N+M=<3 7 (58.3%) 3 (30%) 8 (44.4%) 12 (54.6%) 0 18 (56.3%)
T+N+M>=4 5 (41.7%) 7 (70%) 10 (55.6%) 10 (45.4%) 3 (100%) 14 (43.7%)
Stage 1.000 1.000 1.000
early 1 (8.3%) 0 0 1 (4.6%) 0 1 (3.1%)
advanced 11 (91.7%) 10(100%) 18 (100%) 21 (95.4%) 3 (100%) 31 (96.9%)
Borrmann type .620 .337 .753
I 1 (9.1%) 0 0 2 (9.5%) 0 2 (6.5%)
I I 00 00 0 0
III 9 (81.8%) 9 (90%) 16 (88.9%) 18 (85.7%) 3 (100%) 26 (83.9%)
IV 1 (9.1%) 1(10%) 2 (11.1%) 1 (4.8%) 0 3 (9.7%)Journal of Experimental & Clinical Cancer Research 2009, 28:125 http://www.jeccr.com/content/28/1/125
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be associated with gastric cancer tumorigenesis. Histone
modifications and DNA methylation are important for
the regulation of LIT1 expression to form active or repres-
sive chromatin structure [27]. LIT1 is a non-coding RNA,
like Xist, Tsix and Air, LIT1 RNA plays a critical role in the
bidirectional spreading of inactive chromatin structures
[39], silencing imprinting genes [40] and formating of the
imprinting center (IC) to coordinate imprinting in the
11p15.5 region. Timing of LIT1 RNA expression is vital for
the proper initiation of imprinting genes [41,42]. Prema-
ture termination of the LIT1 transcript leads to LOI in the
proximal region indicating full-length Lit1 RNA is neces-
sary for maintaining the imprinting status [43]. Mouse
Lit1 RNA plays a critical role in silencing at the IC of the
imprinted gene cluster and the transcript length of Lit1
RNA is important for the degree of silencing [44].
And we found patients with LOI of IGF2 in their tumour
had higher increased risk of the lymph node metastasis
than those without (OR = 4.5, 95%CI = 1.084-18.689, p =
0.038). Recently our study found metastatic lymph node
ratio is a useful independent prognostic factor and may
obviate possible confounding factors that are related to
stage migration, and should be considered as an impor-
tant component in the lymph node ategory. Lymph node
ratio category has advantages in providing a more precise
prognostic value than the pN category (5th edition,
UICC). We recommend that classification of nodal status
be established by a combination of both the metastatic
nodes number and ratio, which would be the best cate-
gory to provide both rational lymph node dissection and
the foundation for adjunctive therapy and predict the
prognosis [45]. Ohashi et al reported conventional patho-
logical factors, such as tumor size, depth of submucosal
invasion, and lymphatic invasion, have a significant influ-
ence on lymph node metastasis in submucosal invasive
gastric cancer [46]. Li et al showed depth of invasion,
lymph node metastasis, hepatic and peritoneal metastasis
and surgical curability were significant factors affecting
survival of the gastric carcinoma patients [47]. But we
failed to find such an association. Liu et al found transver-
sal and skipping metastases of sentinel lymph nodes
(SLN) are notable and therefore rational lymphadenec-
tomy should be performed in primary gastric cancer [48].
Some research demonstrated lymph node metastasis were
independent prognostic factors in human gastric carci-
noma [49]. And high expression of mitotic centromere-
associated kinesin (MCAK) and tripartite motif-contain-
ing 29 (TRIM29) are predictors for lymph node metastasis
[50,51]. It might be more appropriate that identifying
patients at high risk of lymph node metastasis who should
be offered gastrectomy rather than endoscopic mucosal
resection, because patients with lymph node metastasis
are more likely to express IGF2 LOI than those without.
Our result was consistent with other studies that LOI of
IGF2 is also important in the carcinogenesis [15,28].
Conclusion
In all, high frequency of IGF2 LOI is present in patients
with gastric cancer in the northeast of China. The associa-
tion of IGF2 LOI with lymph node metastasis may con-
tribute to the development and progression of gastric
cancer.
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